Platelet imipramine binding in patients with posttraumatic stress disorder before and after phenelzine treatment

Ronit Weizman, Nathaniel Laor, Ayala Schujovitsky, Leo Wolmer, Pnina Abramovitz-Schnaider, Ariela Freudstein-Dan, Moshe Rehavi

Research output: Contribution to journalArticlepeer-review

Abstract

Posttraumatic stress disorder (PTSD) is frequently associated with major depressive disorder, and antidepressants have been reported to ameliorate PTSD symptoms in some patients. The present study assessed the number and affinity of platelet imipramine binding sites, as a marker of the serotonin transporter complex, in PTSD male patients (n = 10) before and after phenelzine treatment (30-60 mg/day, for 4 weeks) as well as in comparison to healthy controls (n = 10). In our sample, there was no evidence of a significant difference in the characteristics (B(max) and K(d)) of platelet [3H]imipramine binding between the PTSD patients and the controls and within PTSD patients before and after phenelzine treatment. Moreover, no beneficial effect of phenelzine was detected in the patients (as assessed by PTSD, anxiety, and depression scales).

Original languageEnglish
Pages (from-to)143-150
Number of pages8
JournalPsychiatry Research
Volume63
Issue number2-3
DOIs
StatePublished - 31 Jul 1996

Keywords

  • Affective disorder
  • Anxiety
  • Monoamine oxidase inhibitor
  • Serotonin transporter

Fingerprint

Dive into the research topics of 'Platelet imipramine binding in patients with posttraumatic stress disorder before and after phenelzine treatment'. Together they form a unique fingerprint.

Cite this